Reuters logo
BRIEF-Cerus provides U.S. business update
May 23, 2017 / 12:47 PM / 7 months ago

BRIEF-Cerus provides U.S. business update

May 23 (Reuters) - Cerus Corp

* Cerus provides U.S. business update

* A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets

* Fresenius Kabi has stated that it is working with its suppliers and FDA to resolve this delay

* Cerus Corp says updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to prior range of $43 million to $48 million

* Cerus Corp - believe shortage could “adversely” affect intercept platelet production by impacted blood centers through year end

* Cerus Corp - received notification last week of a pending U.S. supply shortage of a platelet additive solution manufactured and sold by fresenius kabi

* Cerus Corp - pending shortage is due to an unanticipated delay in FDA approval of a plastic component used in manufacture of pas container Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below